All Insights
Showing 121 - 132 of 390
Life Sciences and Healthcare
Investment control in transactions in the life sciences and healthcare sector
Investment control means that additional regulatory approvals are required, affecting the timeline, complexity and costs of a transaction
Life Sciences and Healthcare
Life sciences dealmakers need to anticipate sector-specific factors in European M&A
European regulatory and intellectual property complexities must be addressed when engaging in mergers and acquisitions
Life Sciences and Healthcare
UK government to refresh post-market surveillance requirements for medical devices
New regulations introduced to bring the UK regulatory framework closer in line with international best practice for post-market surveillance requirements
The UK Budget
What do venture capitalists need to know about the UK government's policies?
Tax changes and growth plans pose opportunities and challenges for the venture capital community
Regulatory and compliance
What can UK business expect from regulators in future?
What can be learnt from the UK government's stated approach to regulation and growth?
The UK Budget
How does the UK Budget impact the life sciences and healthcare sector?
Change is afoot as more NHS investment and reforms follow a new industrial strategy and Regulatory Innovation Office
Life Sciences and Healthcare
EU tightens health tech regulations on supply chain disruptions
European Commission clarifies new rules for 2025, mandating early notification of potential medical device supply issues
Life Sciences and Healthcare
European Parliament urges revision of medical devices regulations
EU medtech and diagnostics sectors face critical regulatory updates in new parliamentary resolution
IT and data
The UK Data (Use and Access) Bill – what businesses should be aware of
The wide-ranging bill covers much more than changes to data protection rules
Life Sciences and Healthcare
Italian Medicines Agency provides clarifications in relation to the introduction of decentralised elements in clinical trials
AIFA clarifies organisational aspects, the regulatory framework and data privacy
Life Sciences and Healthcare
England's health and social care sector can expect more change at the Care Quality Commission
Healthcare providers face uncertainty following the rollout of the single assessment framework amid public criticism
Intellectual property
'Commercially reasonable efforts' in licensing agreements: what needs to be considered?
What efforts are actually 'commercially reasonable'?
